Vertex Minerals continues to steadily increase the rate of stoping at Reward gold mine, delivering ore grade material and ...

Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following ...

Vertex Inc. (NASDAQ:VERX) ('Vertex” or the 'Company”), a leading global provider of indirect tax solutions, and CPA.com, the trusted partner in accounting and finance transformation, today announced ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and ...

The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...

These companies could innovate their way to success.

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

If the trends of the first three quarters continue in the fourth, the amount of money raised by Bay State startups could be ...

In addition, Gemini 3 Flash is being made the default model for Google Search’s AI Mode, which responds to user’s searches ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.